NCT03766269 is a Phase 2 clinical trial of Dronabinol in Chronic Pain, sponsored by Daisy Pharma Opioid Venture, LLC.

Who is sponsoring NCT03766269?

NCT03766269 is sponsored by Daisy Pharma Opioid Venture, LLC.

What drugs are being tested in NCT03766269?

Interventions in NCT03766269: Dronabinol.

What condition does NCT03766269 study?

NCT03766269 studies Chronic Pain.

Is NCT03766269 still recruiting?

NCT03766269 is currently status unknown. Last updated 6 December 2018.

Last reviewed 2018-12-06 · How we verify

NCT03766269

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dronabinol Opioid Sparing Evaluation (DOSE) Trial

Status unknown Phase 2 Last updated 6 December 2018

What this trial tests

Phase 2 trial testing Dronabinol in Chronic Pain in 280 participants. Status unknown.

Timeline

1 December 2018

Primary endpoint
1 June 2019

1 July 2019

Quick facts

Lead sponsor	Daisy Pharma Opioid Venture, LLC
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	280
Start date	1 December 2018
Primary completion	1 June 2019
Estimated completion	1 July 2019
Sites	1 location across United States

Drugs / interventions tested

Dronabinol (DRONABINOL) — full drug profile →

Conditions studied

Chronic Pain — all drugs for Chronic Pain →

Sponsor

Daisy Pharma Opioid Venture, LLC

Who can join

18 and older, any sex, with Chronic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will be a 12-week, open-label trial that is designed to evaluate the Opioid-Sparing effect of Dronabinol at ranging doses when coadministered with the opioid analgesics that are currently being prescribed to patients for their chronic pain condition. The purpose of this trial will be to assess the effectiveness of Dronabinol when combined with opioid analgesics to relieve pain at lower opioid doses and to evaluate any reduction of opioid-related side effects. Participants will take the study-drug, Dronabinol, along with their regular prescribed opioids and the results will be evaluated and analyzed according to defined endpoints.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry.
Kurtz JS, Patel NA, Gendreau JL, Yang C, et al · · 2022 · cited 19× · PMID 36259015 · DOI 10.7759/cureus.29167
Applications of Cannabinoids in Neuropathic Pain: An Updated Review.
Arthur P, Kalvala AK, Surapaneni SK, Singh MS. · · 2024 · cited 12× · PMID 37824417 · DOI 10.1615/critrevtherdrugcarriersyst.2022038592

Verify or expand the search:

Other trials of Dronabinol

Trials testing the same drug.

NCT07225777 — Sex Differences in Neurobehavioral Response to THC · Phase 2 · not yet recruiting
NCT06731894 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors · Phase 2 · recruiting
NCT06477952 — DRonabinol Treatment of OSA · Phase 1, PHASE2 · recruiting
NCT05865470 — Age-dependent Effects of Smoked and Oral Delta-9-THC · Phase 1 · recruiting
NCT05519111 — Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain · Phase 2 · recruiting

Other recruiting trials for Chronic Pain

Currently open trials in the same condition.

NCT07491549 — The Effect of Pain Education Group Therapy and Its Impact on Chronic Pain, Kinesiophobia, and Physical Activity · NA · recruiting
NCT07425691 — SPACE for Youth With Chronic Pain · recruiting
NCT07103135 — Optimizing Accelerated TMS for Chronic Pain With Thompson Sampling · Phase 1 · recruiting
NCT06219408 — CIH Stepped Care for Co-occurring Chronic Pain and PTSD · NA · recruiting
NCT07270406 — Healthy Behaviors for Insomnia Prevention in People With HIV and Ongoing Pain · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03766269 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daisy Pharma Opioid Venture, LLC
Last refreshed: 6 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03766269.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing